Acute ischemic stroke
Imaging-guided tenecteplase treatment in an extended time window
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Tenecteplase is a modified tissue plasminogen activator with a longer half-life and higher fibrin specificity than alteplase.
Methods: We conducted a prospective, nonrandomized, pilot study of 0.1 mg/kg IV tenecteplase given 3 to 6 hours after ischemic stroke onset. For a control group, we used patients contemporaneously treated with sub–3-hour 0.9 mg/kg IV alteplase following standard selection criteria. All patients underwent pretreatment and 24-hour perfusion/angiographic imaging with CT or MRI. Eligibility criteria for tenecteplase (but not alteplase) treatment included a perfusion lesion at least 20% greater than the infarct core, with an associated vessel occlusion. Primary outcomes, assessed blind to treatment group, were reperfusion (reduction in baseline–24-hour mean transit time lesion) and major vessel recanalization.
Results: Fifteen patients received tenecteplase, and 35 patients received alteplase. The tenecteplase group had greater reperfusion (mean 74% vs 44% in the alteplase group, p = 0.01) and major vessel recanalization (10/15 tenecteplase vs 7/29 alteplase, p = 0.01). Despite later time to treatment, more tenecteplase patients (10/15 vs 7/35 alteplase, p = 0.001) had major neurologic improvement at 24 hours (NIH Stroke Scale reduction ≥8). Four of the alteplase patients and none of the tenecteplase patients had parenchymal hematoma at 24 hours.
Conclusions: Tenecteplase 0.1 mg/kg, using advanced imaging guidance in an extended time window, may have significant biologic efficacy in acute ischemic stroke. The imaging selection differences between the tenecteplase and alteplase groups prevent a conclusive efficacy comparison. Nonetheless, these results lend support for randomized trials comparing tenecteplase with alteplase, preferably incorporating penumbral/angiographic imaging selection.
CBV = cerebral blood volume; CTA = CT angiography; CTP = perfusion CT; DWI = diffusion-weighted echo-planar spin-echo sequence; ICH = intracranial hemorrhage; MNI = major neurologic improvement; MR = magnetic resonance; mRS = modified Rankin Scale; MTT = mean transit time; NCCT = noncontrast CT; NIHSS = NIH Stroke Scale; PH = parenchymal hematoma; TIMI = Thrombolysis in Myocardial Infarction.
Footnotes
-
Supplemental data at www.neurology.org
Disclosure: M.W.P. and C.R.L. have received honoraria to speak at educational symposia sponsored by Boehringer-Ingelheim (who market alteplase and tenecteplase in Australia). All remaining authors have no disclosures.
Received April 16, 2008. Accepted in final form December 12, 2008.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Tenecteplase in ischemic stroke offers improved recanalizationAnalysis of 2 trialsAndrew Bivard, Xuya Huang, Christopher R. Levi et al.Neurology, June 02, 2017 -
Article
Exploring the relationship between ischemic core volume and clinical outcomes after thrombectomy or thrombolysisChushuang Chen, Mark W. Parsons, Christopher R. Levi et al.Neurology, June 17, 2019 -
Neuroimaging
Application of acute stroke imagingSelecting patients for revascularization therapyTiesong Shang, Dileep R. Yavagal et al.Neurology, September 24, 2012 -
Articles
Identification of the penumbra and infarct core on hyperacute noncontrast and perfusion CTM. W. Parsons, E. M. Pepper, G. A. Bateman et al.Neurology, March 05, 2007